Stanford researchers provide a thorough, straightforward review of the technical capabilities of the CyberKnife System that allow it to be used to treat tumors throughout the body

Dr. Naff, from Sinai Hospital in Baltimore and Johns Hopkins University, describes the unique features of the CyberKnife System, and its use in brain and spine radiosurgery.

Stanford researchers show that fractionated treatment using the CyberKnife System for acoustic neuromas may improve hearing preservation.

Researchers from Baylor University Medical Center used the CyberKnife System to achieve local control for children with some types of CNS tumors.

Stanford University researchers used the CyberKnife System to obtain high rates of tumor control for tumors near (less than 2 mm from) the optic apparatus; over 90% of patients treated maintained or improved their vision.

Researchers from Stanford University used the CyberKnife System to treat trigeminal neuralgia.  Ninety percent of patients treated rated their pain control as excellent with limited facial numbness at 10 months follow-up.

Researchers from Stanford University used the CyberKnife System for adjuvant treatment of brain metastases by targeting post-resection cavities. They obtained a 79% local control rate at 12 months, which compares favorably to historic whole brain radiation treatment results.

Researchers from Baylor University Medical Center used the CyberKnife System to perform fractionated stereotactic radiosurgery on lesions that are difficult to treat in a single fraction approach.

Researchers from Stanford University performed CyberKnife System treatment on 20 GBM patients after tumor resection. The overall median survival was 16 months, which compares favorably to post-surgical external beam radiation therapy.

University of Pittsburgh researchers treated a variety of patients with primary lung cancer, metastatic lung tumors, or recurrent cancer. Using the CyberKnife System they delivered 3 fractions of 20 Gy and concluded it was an effective treatment for patients with medically inoperable recurrent or metastatic lung cancer.

Miami researchers show that image-guided robotic stereotactic radiosurgery of lung tumors with the CyberKnife System in medically inoperable patients with early non-small-cell lung cancer (NSCLC) achieves excellent local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option

Georgetown researchers used the CyberKnife System to deliver 45-60 Gy in 3 fractions to small tumors (including some metastatic tumors) in the outer lung, resulting in 83% local control and 84% overall survival at 12 months.

Georgetown University Researchers performed CyberKnife System radiosurgery on patients with both benign and malignant spinal tumors. The results show pain relief and maintenance of quality of life after the treatment.

Stanford University researchers determined that benign lesions located on the spinal cord can be treated safely and effectively with the CyberKnife System.

Stanford University researchers used the CyberKnife System to treat spinal cord AVMs with fractionated stereotactic radiosurgery.

Georgetown University researchers performed a comparison of external beam radiation therapy to CyberKnife System stereotactic radiosurgery for breast cancer metastasis to the spine.  Outcomes were statistically comparable, even though most of the patients treated with the CyberKnife System had previously undergone external beam radiation therapy.

Researchers from the University of Pittsburgh Medical Center performed the largest published study on spinal radiosurgery. Their results show that single fraction CyberKnife System radiosurgery is safe and effective both as a primary treatment modality and as salvage treatment for spinal tumors.

This article, in French, concludes that the CyberKnife System is a technical improvement to existing technology (HDR brachytherapy) for delivering a boost after EBRT.

Researchers from San Diego’s Radiosurgery Medial Group report that the CyberKnife System can achieve HDR-like dose distributions with excellent conformality and sharp dose fall off.

Stanford University Researchers used the CyberKnife System to treat 41 low-risk prostate cancer patients.  With a median follow-up of 33 months they found no patient had a PSA failure.  They conclude that the early and late toxicity profile and PSA response for prostate treatment using the CyberKnife System are highly encouraging.

Stanford University researchers treated patients with locally advanced pancreatic cancer using the CyberKnife System.  They found it was feasible to achieve local control without significant acute gastrointestinal toxicity using a dose of 25 Gy.

Stanford University researchers found that concurrent IMRT and 5-FU followed by treatment with the CyberKnife System on patients with locally advanced pancreatic cancer results in excellent local control. Overall survival was not affected, and the combined treatment caused more toxicity than radiosurgery alone.

Stanford University researchers found that combining gemcitabine chemotherapy with CyberKnife System treatment resulted in good local control, but that a significant rate of duodenal ulcers occurred.

Researchers from Stanford University treated 20 patients with liver malignancies using the CyberKnife System.  At a median of 7 months they observed limited toxicity and 76% of the treated lesions showed a decrease in size.  The researchers concluded that CyberKnife System treatment to the liver for primary or metastatic malignancies is feasible and safe.

Researchers from the Cleveland Clinic Foundation used the CyberKnife System to treat pig kidneys.  They were able to ablate target tissue while leaving nearby tissue undamaged.

Authors from the Department of Radiology, Aretaieion Hospital, University of Athens, Greece, describe in detail their experience with installation of quality assurance of the CyberKnife G4 System.  Repeated tests showing sub-millimetric targeting accuracy are highlights of this paper.

In a collaboration between Stanford and UCSF researchers, considerable prostate motion was detected during treatment between X-ray acquisitions.  Authors recommend imaging about every 40 seconds to adequately compensate.

Yale University researchers present the foundational work for Accuray’s Monte Carlo dose calculation algorithm along with presenting tests demonstrating the algorithm’s accuracy.

Researchers from Georgetown University obtained CyberKnife System treatment plans with good conformality and homogeneity for oddly shaped lesions in the sensitive skull base region.

Researchers from Munich, Germany demonstrate using phantom tests that Xsight® Spine is accurate to within about 0.5 mm.  They conclude that fiducial-free tracking is a feasible, accurate and reliable approach to non-invasive spine radiosurgery.

Researchers from Georgetown University demonstrate that the Synchrony® Respiratory Motion Tracking System of the CyberKnife System tracks simulated lung tumors with 0.43-0.60 mm precision and a tracking variability of 0.14-0.20 mm.

Researchers from the United Kingdom present an investigation of the ability of the Synchrony® Respiratory Motion Tracking System to correct for tumor motion due to respiration. A reduction in dose misplacement due to movement was found with motion tracking, such that dosimetry for the motion-tracked case approximated that for the no-motion case.

Rotterdam researchers show that the Synchrony Respiratory Motion Tracking System correct for tumor motion due to respiration. A reduction in dose misplacement due to movement was found with motion tracking, such that dosimetry for the motion-tracked case approximated that for the no-motion case.

Researchers at Accuray Incorporated demonstrate that sub-millimetric accuracy for intracranial targets can be obtained with their 6D image registration algorithm.

Researchers from the Netherlands compared CyberKnife System lung radiosurgery using the Synchrony Respiratory Motion Tracking System to a conventionally fractionated 3D conformal radiotherapy (3D-CRT) method, and concluded that the system allows safe dose escalation to moving targets.